The earnings results for Conmed CNMD for Q4 were made public on Wednesday, February 5, 2025 at 04:05 PM.
Here's a comprehensive overview of the announcement.
Earnings
Conmed beat estimated earnings by 12.0%, reporting an EPS of $1.34 versus an estimate of $1.2.
Revenue was up $18.90 million from the same period last year.
Analysis of Past Earnings
The company beat on EPS by $0.06 in the last quarter, resulting in a 5.0% increase share price change the following day.
Here's a look at Conmed's past performance:
Quarter | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
---|---|---|---|---|
EPS Estimate | 0.99 | 0.91 | 0.74 | 1.11 |
EPS Actual | 1.05 | 0.98 | 0.79 | 1.06 |
Revenue Estimate | 318.13M | 332.32M | 306.78M | 332.20M |
Revenue Actual | 316.70M | 332.10M | 312.27M | 327.05M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Conmed management provided guidance for FY 2025, expecting earnings between $4.25 and $4.4 per share.
To track all earnings releases for Conmed visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.